Lipoquimia

Lipoquimia is a Spanish biotechnology company specializing in the design and development of innovative drugs based on Membrane Lipid Therapy (MLT). The company focuses on modulating the composition and structure of cell membrane lipids to regulate cell signaling pathways involved in diseases such as cancer and neurodegeneration. Its lead candidate, 2-hydroxyoleic acid (also known as LAM561 or Minerval), is a first-in-class synthetic fatty acid currently in pivotal clinical trials for the treatment of glioblastoma. Lipoquimia operates as part of a specialized ecosystem in the Balearic Islands, closely linked to the research and development efforts of Laminar Pharmaceuticals.